Literature DB >> 20837685

Putting ACCOMPLISH into context: management of hypertension in 2010.

Finlay A McAlister1, Robert J Herman, Nadia A Khan, Simon W Rabkin, Norm Campbell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20837685      PMCID： PMC2952002          DOI： 10.1503/cmaj.092142

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  13 in total

1.  Active-control equivalence trials and antihypertensive agents.

Authors:  F A McAlister; D L Sackett
Journal:  Am J Med       Date:  2001-11       Impact factor: 4.965

Review 2.  Randomized trials stopped early for benefit: a systematic review.

Authors:  Victor M Montori; P J Devereaux; Neill K J Adhikari; Karen E A Burns; Christoph H Eggert; Matthias Briel; Christina Lacchetti; Teresa W Leung; Elizabeth Darling; Dianne M Bryant; Heiner C Bucher; Holger J Schünemann; Maureen O Meade; Deborah J Cook; Patricia J Erwin; Amit Sood; Richa Sood; Benjamin Lo; Carly A Thompson; Qi Zhou; Edward Mills; Gordon H Guyatt
Journal:  JAMA       Date:  2005-11-02       Impact factor: 56.272

3.  Contradicted and initially stronger effects in highly cited clinical research.

Authors:  John P A Ioannidis
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

4.  Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden.

Authors:  Carlene M M Lawes; Stephen Vander Hoorn; Malcolm R Law; Paul Elliott; Stephen MacMahon; Anthony Rodgers
Journal:  J Hypertens       Date:  2006-03       Impact factor: 4.844

5.  Does it matter how hypertension is controlled?

Authors:  Aram V Chobanian
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

6.  Composite renal endpoints: was ACCOMPLISH accomplished?

Authors:  Hiddo Lambers Heerspink; Dick de Zeeuw
Journal:  Lancet       Date:  2010-02-18       Impact factor: 79.321

7.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

8.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

9.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

Authors:  Michael A Weber; Stevo Julius; Sverre E Kjeldsen; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John H Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; M Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.